Management of Asymptomatic Hypertension with Suspected Left Ventricular Hypertrophy

Diagnostic Approach

The European Society of Cardiology recommends obtaining transthoracic echocardiography to confirm suspected left ventricular hypertrophy (LVH), quantify left ventricular mass index, determine LV architecture, assess for diastolic dysfunction, and evaluate ejection fraction, as LVH confers a 7-fold increase in cardiovascular mortality and 4-fold increase in all-cause mortality, independent of blood pressure 2, 3, 4
The American Heart Association suggests obtaining 12-lead ECG to document baseline rhythm, assess for conduction abnormalities beyond bradycardia, measure QTc interval, and look for ECG evidence of LVH using Cornell voltage-duration product or Sokolow-Lyon criteria 1, 5

The American College of Cardiology recommends initiating losartan 50mg once daily, with a plan to uptitrate to 100mg daily based on blood pressure response, as the LIFE trial demonstrated that losartan was superior to atenolol in reducing cardiovascular events and achieving greater LVH regression in hypertensive patients with LVH 2, 3, 7
The European Society of Cardiology suggests that angiotensin receptor blockers (ARBs), particularly losartan, provide sudden cardiac death reduction benefits that appear independent of blood pressure reduction in patients at high risk 1
The American Heart Association recommends avoiding beta-blockers as first-line therapy despite their cardiovascular benefits, as they worsen bradycardia and are inferior for LVH regression 2, 3, 5

The American College of Cardiology recommends targeting blood pressure <130/80 mmHg, with gradual reduction over several days to weeks to avoid precipitous drops, and implementing home blood pressure monitoring with both sitting and standing measurements to assess for orthostatic hypotension 9
The European Society of Cardiology suggests scheduling follow-up within 2-4 weeks after initiating therapy to assess blood pressure response, monitor for symptomatic bradycardia worsening, and check serum potassium and creatinine 9

The American Heart Association states that LVH regression is associated with improved cardiovascular outcomes independent of blood pressure control, and patients who demonstrate LVH regression on antihypertensive therapy have lower rates of cardiovascular events than those who do not, independent of blood pressure control 2, 3
The European Society of Cardiology recommends that each 39 g/m² reduction in left ventricular mass index is associated with 40% lower risk of cardiovascular events 3, 4